



## Advances in Nanomedicine for Disease Treatment and Diagnosis

Guest Editors:

**Dr. Li Li**

**Dr. Run Zhang**

**Prof. Dr. Zhiping Xu**

**Dr. Anjaneyulu Dirisala**

**Dr. Yuki Mochida**

Deadline for manuscript  
submissions:

**closed (30 September 2023)**

### Message from the Guest Editors

Dear Colleague,

Nanomedicine, integrating nanotechnology, biology and medicine, has emerged for providing better disease treatments and more precise diagnosis. In the recent 20 years, various nanomedicines have been developed by engineering nanomaterials to deliver therapeutic/imaging agents such as drugs, proteins, peptides, imaging probes and photosensitizers to targeted tissues and cells. Several innovative therapeutic strategies, such as personalized nanomedicine, imaging-guided nanomedicine, and combination therapies (photothermal therapy, photodynamic therapy, sonodynamic therapy, and immunotherapy) are making remarkable progress, achieving the goals of early diagnosis and improving treatment efficiency. So far, >20 nanomedicines have been approved by US Food and Drug Administration (FDA) and used in the clinic, and more are in clinical trials, bringing about the revolution of conventional medicine.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)